InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.70
(
-0.25%
)
Bitcoin
58,836.47
(
-2.20%
)
Post# of 12660
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

nmstav

Send PM Follow Ignore
Followers 0
Posts 38
Boards Moderated 0
Alias Born 12/10/2003

nmstav

Re: None

Thursday, 09/06/2007 12:53:30 AM

Thursday, September 06, 2007 12:53:30 AM

Post# of 12660
Dendreon is no longer recruiting patients for the IMPACT Trial

From the DNDN website:

PROSTATE CANCER

IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment)
Dendreon is no longer recruiting patients for the IMPACT Trial.
If you would like to contacted about future trials, contact 1-866-4PROSTATE
(1-866-477-6782) or periodically refer back to this website.

DISCLOSURE OF RISKS
Please note that the safety and effectiveness of this product have not yet been established. As with other anti-cancer treatments, this investigational product may not benefit you and may cause side effects. These side effects could be severe or even life threatening. There may be side effects that are not known or predictable at this time, but that may occur at the time of treatment or later. You should discuss these risks with your physician or a study doctor.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up